Multiple choice

Which of the following statements relating to anti-TNF monoclonal antibody therapies is FALSE?

  1. The risk of latent TB is assessed routinely in immunosuppressed patients by interferon release assays on whole blood.

  2. Clinical characteristics of TB in the setting of anti-TNF therapy include a preponderance of extra-pulmonary disease and poor granuloma formation on histology.

  3. Therapeutic TNF inhibition is associated with significant risk of reactivation of Mycobacterium tuberculosis.

  4. Infliximab is a soluble TNF receptor.

  5. The success of TNF blockade in rheumatoid arthritis (RA) underlines the pivotal proinflammatory role of TNF in this disease.
Reveal answer Fill a bubble to check yourself
D Correct answer
Explanation

Etanercept is the soluble TNF receptor. Infliximab is a monoclonal antibody - as indicated in the last part of the name InflixiMAB. TNF blockade can be achieved by either the use of a chimeric anti-TNF antibody (infliximab, adalimumab) or a soluble TNF receptor (etanercept).

Keep practicing — related questions